{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(4)"],"submitter":["Negandhi AA"],"funding":["Canadian Institutes of Health Research"],"pubmed_abstract":["<h4>Introduction</h4>In this study, 27 genetic polymorphisms that were previously reported to be associated with clinical outcomes in colorectal cancer patients were investigated in relation to overall survival (OS) and disease free survival (DFS) in colorectal cancer patients from Newfoundland.<h4>Methods</h4>The discovery and validation cohorts comprised of 532 and 252 patients, respectively. Genotypes of 27 polymorphisms were first obtained in the discovery cohort and survival analyses were performed assuming the co-dominant genetic model. Polymorphisms associated with disease outcomes in the discovery cohort were then investigated in the validation cohort.<h4>Results</h4>When adjusted for sex, age, tumor stage and microsatellite instability (MSI) status, four polymorphisms were indepen"],"journal":["PloS one"],"pagination":["e61469"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3634085"],"repository":["biostudies-literature"],"pubmed_title":["MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland."],"pmcid":["PMC3634085"],"pubmed_authors":["Dicks E","Negandhi AA","Younghusband BH","Hyde A","Pollett W","Savas S","Green RC","Parfrey P"],"additional_accession":[]},"is_claimable":false,"name":"MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland.","description":"<h4>Introduction</h4>In this study, 27 genetic polymorphisms that were previously reported to be associated with clinical outcomes in colorectal cancer patients were investigated in relation to overall survival (OS) and disease free survival (DFS) in colorectal cancer patients from Newfoundland.<h4>Methods</h4>The discovery and validation cohorts comprised of 532 and 252 patients, respectively. Genotypes of 27 polymorphisms were first obtained in the discovery cohort and survival analyses were performed assuming the co-dominant genetic model. Polymorphisms associated with disease outcomes in the discovery cohort were then investigated in the validation cohort.<h4>Results</h4>When adjusted for sex, age, tumor stage and microsatellite instability (MSI) status, four polymorphisms were indepen","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013","modification":"2026-04-16T21:19:20.091Z","creation":"2026-04-07T14:18:25.277Z"},"accession":"S-EPMC3634085","cross_references":{"pubmed":["23626689"],"doi":["10.1371/journal.pone.0061469"]}}